



16 March 2023

Company Announcements Office
Australian Securities Exchange

Vectus to present at NWR Virtual Healthcare Conference

Vectus Biosystems Limited (Vectus or the Company) is pleased to announce that it will present at the NWR Virtual Healthcare Conference.

Chief Executive Officer Dr Karen Duggan will present at 12:20pm AEDT on Wednesday, 22 March 2023.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link:

https://us02web.zoom.us/webinar/register/WN_3weKNzKdQ86CEsqMCwzWAw

A recording will be available at the above link shortly after the conclusion of the live session and the replay will also be available via the Company's social media channels, with links on the Vectus website.

Questions can be submitted on the day or sent in advance to matt@nwrcommunications.com.au

For more information please visit: <https://nwrcommunications.com/healthconf>

Vectus Biosystems Limited

For more information:

Karen Duggan

Chief Executive Officer and Executive Director

Matthew Wright

NWR Communications

P: 0451 896 420

E: matt@nwrcommunications.com.au

This Vectus announcement was authorised by the Disclosure Committee.

About Vectus Biosystems Limited

Vectus Biosystems Limited is developing a treatment for fibrosis and high blood pressure, which includes the treatment for three of the largest diseases in the fibrotic market, namely heart, kidney and liver diseases. Vectus successfully completed its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX:VBS) and commenced trading on ASX on 23 February 2016, after raising \$5.1 million. Funds from the IPO were predominantly used to develop the Company's lead compound, VB0004, which aims to treat the hardening of functional tissue and high blood pressure. Vectus has conducted a range of successful pre-clinical trials, which have shown that VB0004 slows down the advances of fibrosis, potentially repairs damaged cell tissue and reduces high blood pressure. VB0004 is now progressing through a number of important milestones, including pharmaceutical scale-up and additional toxicity studies. Following successful results, funded by the 2019 convertible note issue, which have all been subsequently been converted into shares, and the 2020 and 2022 share placements and SPP, the Company has funding for its Human Phase Ib trial of VB0004 and to advance the other drugs in its library. Vectus' strategy is to develop and perform early validation of its drug candidates to the point where they may become commercially attractive to potential pharmaceutical partners.

The Company has also developed technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The technology, called Accugen, is owned by Vectus' wholly-owned subsidiary Accugen Pty Limited. The technology offers a time, cost and accuracy benefit compared to currently-available systems. The Company's current stage of investment in Accugen is a commercialisation programme that may include direct sales, distribution partnerships and licensing opportunities.

VECTUS BIOSYSTEMS LIMITED ABN 54 117 526 137

3-11 Primrose Avenue, Rosebery, NSW 2018 Telephone: +61 2 9381 1000 Facsimile: +61 2 9662 1720

Website: www.vectusbiosystems.com.au